For moderate to severe patients 12+ years not adequately controlled with other systemic drugs, including biologics.1
ABBVIE IS COMMITTED
TO SUPPORTING YOUR PATIENTS
As with all no-charge programs, considerations include:
- Fixed program duration‖
- Ongoing PAs and appeals to maintain eligibility
- Program-mandated distribution process
Once enrolled in RINVOQ Complete, commercially eligible patients experiencing initial coverage delays or denials may be able to access their prescribed treatment at no charge while coverage is being established.†
*Formulary Definitions: Preferred means the product is placed on the plan's preferred formulary. Based on formulary status under the pharmacy benefit.
†Eligibility: Available to patients with commercial insurance coverage for RINVOQ who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit
‡Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing health care professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.
§Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.
‖Program duration may be limited by manufacturer terms and conditions.